TriangleHEALTH PROFESSIONAL · SOURCE READING
Antiplatelet therapy
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Polycythemia Vera / Treatment Options for PV
After controlling hematocrit with phlebotomy or cytoreductive therapy, the second principle in treating PV is the use of antiplatelet agents to reduce the risk of thrombosis.
Evidence (antiplatelet therapy):
The double-blind, randomized, phase III European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) studied the use of aspirin in patients with PV.[16]
Source links and citations
The double-blind, randomized, phase III European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) studied the use of aspirin in patients with PV.[16]
Aspirin use was associated with a lower combined risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 % CI, 0.18–0.91).[16][Level of evidence B1]
Source links and citations
The double-blind, randomized, phase III European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) studied the use of aspirin in patients with PV.[16]
The incidence of major bleeding was not significantly increased in the aspirin group.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice